Sunday 18 October 2026
Export RZLT’s income statement to Excel — free account
Rezolute, Inc.
RZLT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 23.1% and free cash flow grew 40.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.58
0.32
−8.21%
Follow RZLT
| Jun '17 | Jun '18 | Jun '19 | Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
2.78 | 0.32 | 1.45 | 3.26 | 21.34 | 61.78 | 20.18 | 13.39 | 14.37 | 9.68 |
Net Debt/EBITDA |
0.23 | 0.06 | 0.49 | 0.48 | 1.19 | 3.63 | 1.78 | 1.73 | 2.04 | 1.26 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.50% | 32.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.02 | 0.54 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.56 | 0.47 | 0.47 | 1.19 | 0.98 | 0.96 | 0.86 | 0.84 | 0.93 | 0.83 |
Capex/Depreciation |
(0.37) | 0.98 | 0.11 | 0.00 | 0.00 | 0.00 | 0.11 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(12,702.56) | (41.70) | (5.23) | (109.15) | (61.05) | (23.16) | (13.31) | — | — | — |
| (273.79%) | (1,307.73%) | 2,962.34% | (446.05%) | (124.92%) | (46.77%) | (38.99%) | (57.73%) | (52.56%) | (59.04%) | |
| (219.99%) | (454.80%) | (443.50%) | (175.16%) | (78.03%) | (42.11%) | (37.51%) | (53.39%) | (48.28%) | (53.82%) | |
ROIC |
(314.30%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (245.12%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(279.20%) | 771.23% | (858.99%) | (277.58%) | (52.18%) | (27.44%) | (51.87%) | (57.46%) | (46.71%) | (78.26%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(16.61) | (11.29) | (424.59) | (4.20) | (2.66) | (2.18) | (0.87) | (1.11) | (0.91) | (0.62) |
Cash per Share |
5.43 | 1.48 | 326.00 | 1.73 | 5.35 | 8.27 | 1.99 | 2.47 | 2.21 | 1.04 |
Shareholders Equity per Share |
10.33 | (3.56) | 49.35 | 1.28 | 3.40 | 8.21 | 2.27 | 2.35 | 2.13 | 0.97 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
10.33 | (3.56) | 49.35 | 1.28 | 3.40 | 8.21 | 2.27 | 2.35 | 2.13 | 0.97 |
Free Cash Flow |
(13.72) | (12.57) | (15.07) | (24.17) | (20.44) | (39.62) | (44.63) | (57.37) | (69.07) | (64.63) |
Working Capital |
3.16 | (4.24) | 3.77 | 7.29 | 40.03 | 149.64 | 99.71 | 119.05 | 159.23 | 99.09 |
Capital Expenditures |
(0.41) | 1.54 | 0.23 | — | — | — | (0.15) | — | — | — |
Net Current Asset Value |
2.83 | (4.46) | 1.64 | 6.92 | 25.48 | 149.16 | 97.36 | 116.92 | 157.78 | 98.35 |
| Other line items | ||||||||||
Quick Ratio |
2.53 | 0.26 | 1.38 | 3.09 | 20.86 | 61.09 | 19.60 | 13.21 | 14.09 | 9.44 |
Depreciation/Fixed assets |
0.21 | 4.27 | 47.77 | 0.55 | 3.41 | 27.31 | (9.64) | (27.19) | (32.82) | (58.98) |
Cash ROIC |
(105.42%) | 542.94% | (113.12%) | (138.22%) | (25.20%) | (13.21%) | (20.47%) | (23.14%) | (20.93%) | (31.00%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(16.12) | (12.68) | (431.10) | (4.20) | (2.66) | (2.18) | (0.87) | (1.11) | (0.91) | (0.62) |
Capex per Share |
(0.49) | 1.39 | 6.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
1.23 | 1.40 | 1.60 | 1.12 | 0.96 | 1.08 | 2.20 | 4.09 | 5.36 | 5.42 |
Average Assets |
10.77 | 6.57 | 7.38 | 11.61 | 26.79 | 97.51 | 138.07 | 128.23 | 154.11 | 144.17 |
Average Common Equity |
8.65 | 2.28 | (1.10) | 4.56 | 16.73 | 87.79 | 132.82 | 118.59 | 141.57 | 131.41 |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | — | — | 0.00 | — | — | — |
Columns are period end dates · fundamentals updated 2 Oct 2026